Details for Patent: 10,052,267
Which drugs does patent 10,052,267 protect, and when does it expire?
Patent 10,052,267 protects QBREXZA and is included in one NDA.
This patent has nine patent family members in six countries.
Summary for Patent: 10,052,267
| Title: | Topical glycopyrrolate formulations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Michael Johnston, Robert James Houlden | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Rose U LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US15/662,166 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,052,267 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 10,052,267: Glycopyrrolate Solution, Hyperhidrosis Wipe, and Patent LandscapeUS Patent 10,052,267 protects a topical glycopyrrolate formulation built around four technical elements: glycopyrrolate salt, a defined ethanol-water solvent system, a citric-acid buffer, and a mildly acidic pH. Dependent claims narrow the formulation to glycopyrrolate hydrobromide or glycopyrrolate p-toluenesulfonate, approximately 2% or 4% drug concentration, approximately 60:40 ethanol-water, and pH near 4.5. Separate claims cover an individually packaged wipe and topical treatment of hyperhidrosis. The claim structure is closely aligned with commercial glycopyrronium cloth products, including Qbrexza. What does US Patent 10,052,267 protect?The patent has three claim categories:
The independent composition claim is claim 1. It requires every limitation listed below:
A competing product that omits one required limitation may avoid literal infringement of claim 1, although dependent claims, equivalents, manufacturing claims, or other patent families could remain relevant. How should claim 1 be construed?Claim 1 is a narrow formulation claim rather than a broad claim to topical glycopyrrolate generally. The central limitation is the combination of composition parameters. The patent does not claim every glycopyrrolate formulation, every topical anticholinergic product, or every treatment of hyperhidrosis. Active pharmaceutical ingredientThe claim covers a glycopyrrolate compound in salt form. The listed counterions include:
Claims 7 and 8 specifically select the hydrobromide and p-toluenesulfonate salts. These dependent claims are commercially significant because glycopyrronium tosylate, also known as glycopyrrolate p-toluenesulfonate, is the active salt used in Qbrexza. The claim language appears directed to a salt of glycopyrrolate rather than only the free base. Salt selection can affect solubility, stability, crystallinity, manufacturing, and skin delivery. Ethanol-water solvent systemClaim 1 covers an ethanol-water ratio from approximately 50:50 to 60:40 by weight. Claim 5 narrows the ratio to approximately 60:40. Claim 6 narrows the ethanol concentration to approximately 53.7% to 57.3% w/w, with water making up the balance. This limitation is important because it gives the claim a measurable formulation boundary. A formulation containing approximately 55% ethanol and 45% water would fall within claim 6, assuming the remaining claim limitations are met. A formulation using a materially different solvent system, such as predominantly water, is outside the literal scope of these limitations. The ratio is measured by weight, not volume. That distinction matters in product testing and infringement analysis. Buffer and pH limitationsThe buffer must contain citric acid and either sodium citrate or tromethamine. The total acid-plus-base concentration must be approximately 0.2% to 0.5% w/w. The pH must be approximately 3.5 to 6 at 25°C. Claims 2 and 3 narrow the pH to approximately 4 to 5 and approximately 4.5, respectively. These claims create a strong product-specific position where a commercial formulation uses citric acid, sodium citrate or tromethamine, and a pH centered near 4.5. The phrase "at an acid:base ratio sufficient to maintain" the specified pH makes the exact ratio functionally dependent on the formulation. The claim does not provide one fixed acid-to-base numerical ratio. Laboratory testing would likely examine the actual acid and base concentrations, final pH, temperature, and analytical method. What are the dependent claims worth commercially?The dependent claims provide fallback positions if the broad composition claim is challenged or narrowed.
Claim 4 is materially different from the concentration and pH claims. It requires a degradation result of less than 1% during storage at 0°C to 25°C for at least one of several periods. This may require stability testing rather than simple inspection of a product label. Claims 14 and 15 expand the formulation concept to polymer-containing products. Claim 15 identifies polyvinylpyrrolidone and a butyl ester of polyvinylmethylether/maleic anhydride copolymer. These limitations may be relevant to adhesion, residence time, film formation, or controlled deposition on skin. What formulations are protected by US 10,052,267?A formulation is a strong literal candidate for claim coverage if it has the following profile:
The claim does not require the formulation to be packaged in a wipe unless claims 16-18 are asserted. A bottle, vial, pump, applicator, or other container could potentially satisfy claims 1-15 if its formulation meets the required limitations. What does the patent protect about wipes?Claims 16-18 cover an individually packaged wipe for treating hyperhidrosis. The wipe must be loaded with the claimed glycopyrrolate solution and contained in a pouch resistant to leakage. Claim 17 covers a broad range of wipe substrates:
Claim 18 narrows the pouch to one with an inner lining of linear low-density polyethylene, or LLDPE. The wipe claims therefore combine a formulation limitation with a packaging and delivery format. A wipe using glycopyrrolate in a materially different formulation may avoid these claims even if it treats the same condition. Conversely, a product using the claimed formulation in a pouch may face risk even if the substrate differs from the commercial reference product, because claim 17 covers multiple substrate classes. What are the method-of-use claims?Claims 19 and 20 cover topical treatment of hyperhidrosis in a mammal. Claim 19 covers topical administration of the solution. Claim 20 covers topical administration of the wipe after removal from its pouch. The method claims require:
The method claims are narrower than a generic claim to treating sweating because they incorporate the composition or wipe limitations through dependency. A product label that directs users to apply the claimed formulation to hyperhidrotic areas may be relevant to induced or contributory infringement theories, depending on the product’s composition and commercial instructions. When does US Patent 10,052,267 lose exclusivity?US Patent 10,052,267 issued on August 21, 2018. Its enforceable term is determined by the earliest effective US nonprovisional filing date in the priority chain, adjusted for patent term adjustment and subject to any terminal disclaimer. A provisional filing date does not normally establish the patent-term start date. The patent number and claim text alone do not establish a legally reliable expiration date. The controlling records are the patent’s front page, continuity data, Patent Center transaction history, patent-term adjustment calculation, and any terminal disclaimer filed with the USPTO.[1] The patent’s practical exclusivity also depends on:
What is the FDA and Orange Book status of the relevant product?Qbrexza, a glycopyrronium cloth, was approved by the FDA for primary axillary hyperhidrosis in patients 9 years of age and older. The product contains glycopyrronium tosylate and is administered as a single-use topical cloth.[2] The FDA-approved product is commercially relevant to this patent because the claimed architecture includes:
The FDA Orange Book is the controlling source for current patent listings and regulatory exclusivity. Orange Book entries may change through delisting, patent expiry, submission of new patent information, or FDA administrative action.[3] Patent 10,052,267 should therefore be evaluated together with every other patent listed for the applicable Qbrexza NDA, rather than treated as the complete product estate. FDA exclusivity and patent exclusivity are separate. A drug may have no remaining regulatory exclusivity but still face listed patent barriers. Conversely, patent expiry does not itself eliminate other requirements for ANDA approval. What Paragraph IV challenges and generic-entry risks exist?A generic applicant seeking approval for a glycopyrronium topical product could pursue several strategies:
The principal technical design-around routes are changing at least one required limitation:
These routes are not automatically safe. A modified product could still implicate other patents, doctrine-of-equivalents arguments, or noninfringement disputes over overlapping ranges. Which companies are relevant to the patent landscape?The commercial landscape includes several company groups:
Almirall completed its acquisition of Dermira in 2020, making Almirall the principal commercial successor for Qbrexza-related assets.[4] The patent itself is only one part of the intellectual-property position. Know-how concerning cloth saturation, pouch barrier performance, uniform dosing, stability, and manufacturing yield may create practical barriers even after patent expiry. How strong is the patent estate?The patent has meaningful strength against products that copy the commercial formulation architecture. Its strongest features are:
Potential vulnerabilities include:
The estate is stronger against a close copy than against a redesigned generic formulation. A generic manufacturer can target the formulation limitations rather than challenge every claim directly. Does biosimilar risk apply?No. Glycopyrrolate is a small-molecule active ingredient, not a biologic. Biosimilar approval under the Public Health Service Act is not the relevant pathway. The principal competitive threat is an ANDA generic or, for a materially modified product, a 505(b)(2) application. What litigation and settlement issues should be reviewed?A complete litigation assessment requires the federal docket, USPTO records and FDA Orange Book history. The relevant questions are:
Settlement terms in pharmaceutical patent cases may include launch dates, licenses, authorized-generic commitments, supply agreements and restrictions on challenge rights. These terms can materially alter the practical entry date even when the patent’s nominal expiration date remains unchanged. What is the competitive position versus other hyperhidrosis treatments?Qbrexza competes with aluminum chloride products, iontophoresis, botulinum toxin injections, oral anticholinergics and other topical therapies. Its principal differentiation is topical anticholinergic delivery through a pre-moistened cloth. The patent’s coverage is most relevant to competitors attempting to reproduce that combination of:
Products using aluminum chloride, oxybutynin, botulinum toxin, or a non-glycopyrrolate active ingredient generally fall outside this patent’s composition claims, although they may be subject to separate patents. Key Takeaways
FAQs About US Patent 10,052,267Does US 10,052,267 cover glycopyrronium tosylate?Yes. Claim 8 expressly covers a glycopyrrolate compound whose counterion is prepared from p-toluenesulfonic acid, corresponding to glycopyrrolate p-toluenesulfonate or glycopyrronium tosylate, when the other claim 1 limitations are met. Does the patent cover a glycopyrrolate cream?Not necessarily. A cream would need to satisfy the composition limitations, including the ethanol-water ratio, citric-acid buffer, pH and glycopyrrolate concentration. A conventional emulsion cream would not automatically fall within the claims. Can a generic avoid the patent by using glycopyrrolate hydrobromide?Potentially, but not automatically. Hydrobromide is expressly covered by claim 7 when the formulation also meets the requirements inherited from claim 1. Is a product at pH 6.1 outside claim 1?Likely outside the literal pH range of claim 1, which ends at approximately pH 6.0. The legal result would depend on the measured pH, the meaning of "about," and any asserted equivalents theory. Does a different wipe material avoid claims 16 and 17?Not necessarily. Claim 17 covers multiple substrate categories, including nonwoven, paper, woven, knitted and other materials. A different substrate may still fall within the claim if it is loaded with the claimed solution and used in the claimed packaged wipe. Is the patent relevant to oral glycopyrrolate products?The patent is directed to topical solutions, wipes and topical treatment of hyperhidrosis. An oral glycopyrrolate product would generally not satisfy the topical composition, wipe or topical-administration limitations. Sources
More… ↓ |
Drugs Protected by US Patent 10,052,267
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,052,267
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2008314628 | ⤷ Start Trial | |||
| Australia | 2014203072 | ⤷ Start Trial | |||
| Canada | 2702830 | ⤷ Start Trial | |||
| European Patent Office | 2200550 | ⤷ Start Trial | |||
| European Patent Office | 3415127 | ⤷ Start Trial | |||
| Spain | 2671874 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
